These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 3591312)

  • 1. In vitro susceptibility of Campylobacter pyloridis to cimetidine, sucralfate, bismuth and sixteen antibiotics.
    Andreasen JJ; Andersen LP
    Acta Pathol Microbiol Immunol Scand B; 1987 Apr; 95(2):147-9. PubMed ID: 3591312
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Susceptibility of clinical isolates of Campylobacter pyloridis to 11 antimicrobial agents.
    McNulty CA; Dent J; Wise R
    Antimicrob Agents Chemother; 1985 Dec; 28(6):837-8. PubMed ID: 2935076
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Susceptibility of clinical isolates of Campylobacter pylori to 24 antimicrobial and anti-ulcer agents.
    Glupczynski Y; Delmee M; Bruck C; Labbe M; Avesani V; Burette A
    Eur J Epidemiol; 1988 Jun; 4(2):154-7. PubMed ID: 3402574
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Response of Campylobacter pyloridis to antibiotics, bismuth and an acid-reducing agent in vitro--an ultrastructural study.
    Armstrong JA; Wee SH; Goodwin CS; Wilson DH
    J Med Microbiol; 1987 Dec; 24(4):343-50. PubMed ID: 3694664
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antibacterial activity of sucralfate and bismuth subsalicylate in simulated gastric fluid.
    Kappstein I; Engels I
    Eur J Clin Microbiol; 1987 Apr; 6(2):216-7. PubMed ID: 3595590
    [No Abstract]   [Full Text] [Related]  

  • 6. The minimum inhibitory and bactericidal concentrations of antibiotics and anti-ulcer agents against Campylobacter pyloridis.
    Goodwin CS; Blake P; Blincow E
    J Antimicrob Chemother; 1986 Mar; 17(3):309-14. PubMed ID: 3700291
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The minimum inhibitory concentrations of various bismuth salts against Campylobacter pylori.
    Vogt K; Warrelmann M; Hahn H
    Zentralbl Bakteriol; 1989 Sep; 271(3):304-10. PubMed ID: 2803458
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vitro synergistic activity between bismuth subcitrate and various antimicrobial agents against Campylobacter pyloridis (C. pylori).
    Van Caekenberghe DL; Breyssens J
    Antimicrob Agents Chemother; 1987 Sep; 31(9):1429-30. PubMed ID: 3674850
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antibacterial action of bismuth in relation to Campylobacter pyloridis colonization and gastritis.
    Marshall BJ; Armstrong JA; Francis GJ; Nokes NT; Wee SH
    Digestion; 1987; 37 Suppl 2():16-30. PubMed ID: 3622946
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vivo susceptibility of Campylobacter pylori.
    Graham DY; Klein PD; Opekun AR; Smith KE; Polasani RR; Evans DJ; Evans DG; Alpert LC; Michaletz PA; Yoshimura HH
    Am J Gastroenterol; 1989 Mar; 84(3):233-8. PubMed ID: 2919580
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative susceptibilities of Campylobacter pylori to norfloxacin and other agents.
    Shungu DL; Nalin DR; Gilman RH; Gadebusch HH; Cerami AT; Gill C; Weissberger B
    Antimicrob Agents Chemother; 1987 Jun; 31(6):949-50. PubMed ID: 3619429
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of oral bismuth subsalicylate on Campylobacter pylori and on healing and relapse rate of peptic ulcer.
    Eberhardt R; Kasper G
    Rev Infect Dis; 1990; 12 Suppl 1():S115-9. PubMed ID: 2406852
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of antimicrobial activity of zinc chloride and bismuth subsalicylate against clinical isolates of Helicobacter pylori.
    Yakoob J; Abbas Z; Usman MW; Awan S; Naz S; Jafri F; Hamid S; Jafri W
    Microb Drug Resist; 2014 Aug; 20(4):305-9. PubMed ID: 23844851
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vitro susceptibility of Campylobacter jejuni and Campylobacter coli isolated in Denmark to fourteen antimicrobial agents.
    Andreasen JJ
    Acta Pathol Microbiol Immunol Scand B; 1987 Jun; 95(3):189-92. PubMed ID: 3630712
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bismuth subsalicylate in the prevention of colonization of infant mice with Campylobacter jejuni.
    Hänninen ML
    Epidemiol Infect; 1990 Jun; 104(3):397-404. PubMed ID: 2347383
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Effect of bismuth subsalicylate versus cimetidine on Campylobacter pylori, ulcer healing and rate of recurrence].
    Eberhardt R; Kasper G; Dettmer A; Höchter W; Hagena D
    Med Klin (Munich); 1988 May; 83(12):402-5. PubMed ID: 3043160
    [No Abstract]   [Full Text] [Related]  

  • 17. Antimicrobial susceptibility of Campylobacter jejuni with special reference to resistance patterns of Canadian isolates.
    Karmali MA; De Grandis S; Fleming PC
    Antimicrob Agents Chemother; 1981 Apr; 19(4):593-7. PubMed ID: 7247381
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vitro antibacterial activity of bismuth subsalicylate.
    Cornick NA; Silva M; Gorbach SL
    Rev Infect Dis; 1990; 12 Suppl 1():S9-10. PubMed ID: 2305178
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Interaction of bismuth subsalicylate with fruit juices, ascorbic acid, and thiol-containing substrates to produce soluble bismuth products active against Clostridium difficile.
    Mahony DE; Woods A; Eelman MD; Burford N; Veldhuyzen van Zanten SJ
    Antimicrob Agents Chemother; 2005 Jan; 49(1):431-3. PubMed ID: 15616328
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The gastroduodenal mucus barrier and its role in protection against luminal pepsins: the effect of 16,16 dimethyl prostaglandin E2, carbopol-polyacrylate, sucralfate and bismuth subsalicylate.
    Copeman M; Matuz J; Leonard AJ; Pearson JP; Dettmar PW; Allen A
    J Gastroenterol Hepatol; 1994; 9 Suppl 1():S55-9. PubMed ID: 7881020
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.